granisetron transdermal system + Granisetron IV

Phase 1Completed
0 watching 0 views this weekπŸ’€ Quiet
33
Hype Score

Development Stage

βœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chemotherapy Induced Nausea and Vomiting

Conditions

Chemotherapy Induced Nausea and Vomiting

Trial Timeline

May 1, 2012 β†’ Dec 1, 2016

About granisetron transdermal system + Granisetron IV

granisetron transdermal system + Granisetron IV is a phase 1 stage product being developed by Kyowa Kirin for Chemotherapy Induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT01596400. Target conditions include Chemotherapy Induced Nausea and Vomiting.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01596400Phase 1Completed

Competing Products

20 competing products in Chemotherapy Induced Nausea and Vomiting

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
RoxadustatAstellas PharmaPhase 2
52
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
77
Sancuso + IV granisetronKyowa KirinPhase 1
33
palonesetronEisaiPhase 2
52
GranisetronKyowa KirinPhase 3
77
Sancuso + IV granisetronKyowa KirinPhase 1
33
ONO-7746Ono PharmaceuticalPhase 1
33
ONO-2910 + PlaceboOno PharmaceuticalPhase 2
52
PROCRIT 40,000 IU QW + PlaceboJohnson & JohnsonPhase 2
52
Epoetin alfaJohnson & JohnsonPhase 2
52
Hetrombopag Olamine + Hetrombopag Olamine οΌ›Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + Matching placeboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
77